Table 2.

Top 10 KEGG pathways potentially affected by the differentially expressed miRNAs in each clinical group evaluated: tumor size, LN, and REC status (ranked by p-value)

#	KEGG pathways	p-value	# genes	# miRNAs
	Tumor size (≥5 cm, < 5 cm)
1	Ubiquitin mediated proteolysis	1.46E-05	40	7
2	Circadian rhythm	0.002970639	14	7
3	Proteoglycans in cancer	0.002970639	42	7
4	Renal cell carcinoma	0.004487894	18	7
5	Signaling pathways regulating pluripotency of stem cells	0.004646529	33	6
6	Endocytosis	0.004646529	44	8
7	Glioma	0.007370446	17	7
8	Oocyte meiosis	0.015388458	25	7
9	RNA degradation	0.022814164	21	6
10	Prolactin signaling pathway	0.022814164	17	6
	LN status
1	Mucin type O-Glycan biosynthesis	3.42E-10	14	8
2	Proteoglycans in cancer	6.78E-10	32	9
3	Signaling pathways regulating pluripotency of stem cells	3.68E-07	55	9
4	TGF-beta signaling pathway	3.17E-06	68	8
5	Glycosaminoglycan biosynthesis – heparan sulfate/heparin	5.72E-06	38	7
6	Hippo signaling pathway	6.54E-06	2	2
7	FoxO signaling pathway	6.94E-06	49	8
8	Circadian rhythm	2.90E-05	52	9
9	ErB signaling pathway	3.54E-05	44	9
10	Phosphatidylinositol signaling system	6.34E-05	25	7
	REC status
1	Prion diseases	1.07E-05	10	8
2	Proteoglycans in cancer	1.07E-05	91	20
3	Mucin type O-Glycan biosynthesis	1.34E-05	15	12
4	Cell adhesion molecules (CAMs)	1.84E-05	65	18
5	TGF-beta signaling pathway	3.45E-05	40	16
6	Axon guidance	3.45E-05	65	16
7	Oxytocin signaling pathway	0.001164	76	18
8	N-Glycan biosynthesis	0.003947	21	15
9	Thyroid hormone signaling pathway	0.003947	53	19
10	Signaling pathways regulating pluripotency of stem cells	0.004389	65	20